Abstract:Background: Acute myelogenous leukemia (AML) is nosocomial with the highest pediatric mortality rates and a relatively poor prognosis. C4.4A ( LYPD3 ) is a tumorigenic and high-glycosylated cell surface protein that has been proven to be linked with the carcinogenic effects in solid tumors, but no hematologic tumors have been reported. We focus on exploring the molecular mechanism of LYPD3 in the regulation of the occurrence and development of AML to provide a research basis for the screening of markers related to the treatment and prognosis. Methods: Datasets on RNA Sequencing (RNA-seq) and mRNA expression profiles of 510 samples were obtained from The Cancer Genome Atlas Program/The Genotype-Tissue Expression (Tcga-gtex) on 10 March 2021, which included the information on 173 AML tumorous tissue samples and 337 normal blood samples. The differential expression, identification of prognostic genes based on the COX regression model, and LASSO regression were analyzed. In order to better verify, experiments including gene knockdown mediated by small interfering RNA (siRNA), cell proliferation assays, and Western blot were prefomed. We studied the possible associated pathways through which LYPD3 may have an impact on the pathogenesis and prognosis of AML by gene set enrichment analysis (GSEA). Results: A total of 11,490 differential expression genes (DEGs) were identified. Among them, 4,164 genes were upregulated, and 7,756 genes were downregulated. The univariate Cox regression analysis and LASSO regression analysis found that 28 genes including LYPD3 , DNAJC8 , and other genes were associated with overall survival (OS). After multivariate Cox analysis, a total of 10 genes were considered significantly correlated with OS in AML including LYPD3 , which had a poor impact on AML ( p <0.05). The experiment results also supported the above conclusion. We identified 25 pathways, including the E2F signaling pathway, p53 signaling pathway, and PI3K_AKT signaling pathway, that were significantly upregulated in AML samples with high LYPD3 expression ( p < 0.05) by GSEA. Further, the results of the experiment suggested that LYPD3 participates in the development of AML through the p53 signaling pathway or/and PI3K/AKT signaling pathway. Conclusion: This study first proved that the expression of LYPD3 was elevated in AML, which was correlated with poor clinical characteristics and prognosis. In addition, LYPD3 participates in the development of AML through p53 or/and the PI3K/AKT signaling pathway.

G Protein-Coupled Receptor 183 Plays a Prognostic Factor in Acute Myeloid Leukemia by Regulating Immune Regulation

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

Expression and Clinical Significance of Phospholipase D1 in De Novo Acute Myeloid Leukemia

Expression Characteristics and Prognosissignificance of Mirna-181A in Acute Myeloid Leukemia with Normal Karyotype

Downregulation of GNA15 Inhibits Cell Proliferation via P38 MAPK Pathway and Correlates with Prognosis of Adult Acute Myeloid Leukemia With Normal Karyotype

SH3BGRL As a Novel Prognostic Biomarker is Down-Regulated in Acute Myeloid Leukemia

LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia

Prognostic Impact of ARHGAP43(SH3BP1) in Acute Myeloid Leukemia

Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML

Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia

ITGAL Infers Adverse Prognosis and Correlates with Immunity in Acute Myeloid Leukemia

Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML

High Expression of LOC541471, GDAP1, SOD1, and STK25 is Associated with Poor Overall Survival of Patients with Acute Myeloid Leukemia.

Study On the Expression of 14-3-3ζ in Acute Myeloid Leukemic Cell Lines

Identification of Molecular and Immune Prognostic Classifiers of Acute Myeloid Leukemia

High expression of ARHGEF5 predicts unfavorable prognosis in acute myeloid leukemia

High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia

Prognostic role of chemokine-related genes in acute myeloid leukemia

Prognostic implications of cGAS and STING gene expression in acute myeloid leukemia

GPR68 Supports AML Cells Through the Calcium/calcineurin Pro-Survival Pathway and Confers Chemoresistance by Mediating Glucose Metabolic Symbiosis

High-expression of the Innate-Immune Related Gene UNC93B1 Predicts Inferior Outcomes in Acute Myeloid Leukemia